In contrast to the aforementioned studies, PER2 seems to have an opposite effect on the treatment response in ER breast cancer cells (MDA-MB-231) suggesting cell and genotype-specific circadian control of apoptotic and cell cycle processes [53]. This evidence concerns the gene PER2 and breast carcinoma.